Donanemab vs Nivolumab

Donanemab vs Nivolumab: Overview

This comparison examines the pharmacological differences between Donanemab and Nivolumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab — 27 days.

Chemical Properties

Type: Donanemab — Antibody; Nivolumab — Antibody.